Security key
M40527109
Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (ENTX)
CUSIP: M40527109
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Ordinary shares, par value NIS 0.0000769 per share
- Shares outstanding
- 45,504,462
- Total 13F shares
- 7,871,783
- Share change
- -1,471,094
- Total reported value
- $8,677,875
- Price per share
- $1.11
- Number of holders
- 26
- Value change
- -$1,722,017
- Number of buys
- 13
- Number of sells
- 11
Report period
Q1 2026
Institutions
26
Top holders
10
ENTX full security history
Previous quarter: Q4 2025
Entera Bio Ltd. SEC filings
Entera Bio Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M40527109
Recent filing periods:
Top shareholders of ENTX - Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| OPKO HEALTH, INC. |
13D/G
|
— |
8.1%
|
3,685,226
|
$8,660,281 | $0 | 16 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
13D/G
|
Company |
2.6%
from 13D/G
|
1,193,653
|
$2,315,687 | — | 31 Dec 2025 | |
| Geno J. Germano |
3/4/5
|
Director |
0.09%
|
40,000
|
$52,000 | +$55,800 | 09 Mar 2026 | |
| Steven D. Rubin |
3/4/5
|
Director |
0.03%
|
15,000
|
$22,350 | +$19,450 | 12 Feb 2026 | |
| Knoll Capital Management, LLC |
13F
3/4/5
|
Company · 10%+ Owner |
13%
|
5,881,879
|
$11,410,845 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.4%
|
627,330
|
$1,217,020 | — | 31 Dec 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
1.3%
|
596,585
|
$1,157,374 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.6%
|
275,073
|
$533,642 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.33%
|
148,668
|
$288,416 | — | 31 Dec 2025 | |
| Seven Fleet Capital Management LP |
13F
|
Company |
0.3%
|
135,318
|
$262,517 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.24%
|
108,001
|
$209,522 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.16%
|
74,064
|
$143,685 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.14%
|
64,910
|
$125,925 | — | 31 Dec 2025 | |
| SIGNATURE ESTATE & INVESTMENT ADVISORS LLC |
13F
|
Company |
0.1%
|
47,328
|
$91,816 | — | 31 Dec 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.09%
|
43,140
|
$83,692 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.09%
|
40,230
|
$78,046 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
21,136
|
$41,003 | — | 31 Dec 2025 | |
| Gem Investment Advisors, LLC |
13F
|
Company |
0.04%
|
19,135
|
$37,122 | — | 31 Dec 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.04%
|
17,142
|
$33,255 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
15,000
|
$29,100 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.03%
|
12,327
|
$23,914 | — | 31 Dec 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.03%
|
11,890
|
$23,000 | — | 31 Dec 2025 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0.02%
|
10,000
|
$19,400 | — | 31 Dec 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
51
|
$99 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
17
|
$33 | — | 31 Dec 2025 | |
| Gerald M. Lieberman |
3/4/5
|
Director |
—
mixed-class rows
|
406,668
mixed-class rows
|
$823,723 | — | 01 Jan 2026 | |
| Miranda Jayne Toledano |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
926,575
mixed-class rows
|
$772,186 | +$19,912 | 29 Dec 2025 | |
| Phillip Schwartz |
3/4/5
|
President of R&D, Director |
—
class O/S missing
|
607,410
|
$601,336 | — | 20 Jan 2022 | |
| Sean Ellis |
3/4/5
|
Director |
—
mixed-class rows
|
221,603
mixed-class rows
|
$231,360 | +$34,620 | 05 Mar 2026 | |
| Yonatan Malca |
3/4/5
|
Director |
—
mixed-class rows
|
110,921
mixed-class rows
|
$185,024 | — | 01 Jan 2026 | |
| Gerald M. Ostrov |
3/4/5
|
Director |
—
mixed-class rows
|
109,162
mixed-class rows
|
$180,820 | — | 01 Jan 2026 | |
| Ramesh Ratan |
3/4/5
|
U.S.based CFO |
—
class O/S missing
|
10,000
|
$9,900 | — | 19 Jan 2022 | |
| Spiros Jamas |
3/4/5
|
Chief Executive Officer |
—
class O/S missing
|
10,000
|
$9,900 | — | 18 Jan 2022 | |
| Roger Garceau |
3/4/5
|
Director |
—
class O/S missing
|
108,333
|
— | — | 01 Jan 2024 | |
| Ron Mayron |
3/4/5
|
Director |
—
class O/S missing
|
108,333
|
— | — | 01 Jan 2024 | |
| Arthur C. Santora II |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
35,000
|
— | — | 24 Apr 2023 | |
| Haya Taitel |
3/4/5
|
Director |
—
class O/S missing
|
33,505
|
— | +$11,100 | 10 Feb 2026 |
Institutional Holders of Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (ENTX) as of Q1 2026
As of 31 Mar 2026,
Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (ENTX) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,871,783 shares.
The largest 10 holders included
Knoll Capital Management, LLC, RENAISSANCE TECHNOLOGIES LLC, Parkman Healthcare Partners LLC, CITADEL ADVISORS LLC, Seven Fleet Capital Management LP, MARSHALL WACE, LLP, NORTHERN TRUST CORP, XTX Topco Ltd, Schonfeld Strategic Advisors LLC, and SIGNATURE ESTATE & INVESTMENT ADVISORS LLC.
This page lists
26
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
22
Q1 2026 holders
26
Holder diff
4
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.